1127252-92-9

Prasugrel-d₅ is intended for use as an internal standard for the quantification of prasugrel by GC- or LC-MS. Prasugrel is a prodrug form of the platelet purinergic P2Y₁₂ receptor antagonist R-99224. Prasugrel (0.3 and 3 mg/kg) inhibits ex vivo washed platelet aggregation in rat platelet rich-plasma. In vivo, prasugrel prevents thrombus formation (ED₅₀ = 0.68 mg/kg) and increases tail bleeding time in rats. Formulations containing prasugrel have been used in the prevention of blood clots.

A novel labelled antiplatelet agent; it is a third-generation thienopyridine. Antiplatelet agent Prasugrel showed greater platelet inhibition and decreased incidence of ischemic events than Clopidogrel but may induce increased incidence of bleeding in patient with acute coronary syndrome

P2Y12 Receptor

Store at -20°C

[1] A. SUGIDACHI. Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type Gi‐linked P2T antagonist, CS‐747[J]. British Journal of Pharmacology, 2001, 132 1. DOI: 10.1038/sj.bjp.0703761
[2] ATSUHIRO SUGIDACHI. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties[J]. British Journal of Pharmacology, 2009, 129 7: 1439-1446. DOI: 10.1038/sj.bjp.0703237